These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3554975)

  • 1. Presence of HTLV-III antibodies in immune serum globulin preparations.
    Lai-Goldman M; McBride JH; Howanitz PJ; Rodgerson DO; Miles JA; Peter JB
    Am J Clin Pathol; 1987 May; 87(5):635-9. PubMed ID: 3554975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of specimen treatment on nonreactive HTLV-III sera.
    McBride JH; Howanitz PJ; Rodgerson DO; Miles J; Peter JB
    AIDS Res Hum Retroviruses; 1987; 3(3):333-40. PubMed ID: 3325086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of antibodies to HTLV-III in quality-assurance sera.
    Howanitz PJ; McBride JH; Kliewer KE; Rodgerson DO
    Clin Chem; 1986 May; 32(5):773-7. PubMed ID: 3009051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin.
    Stapleton JT; Jansen R; Lemon SM
    Gastroenterology; 1985 Sep; 89(3):637-42. PubMed ID: 2991071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of immune globulins in relation to HTLV-III.
    FDA Drug Bull; 1986 Jun; 16(1):3. PubMed ID: 3015704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of biological reagents for presence of human immunodeficiency virus-1 (HIV-1) antigens.
    Howanitz PJ; McBride JH; Rodgerson DO
    Eur J Clin Chem Clin Biochem; 1991 Mar; 29(3):173-8. PubMed ID: 2070013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique pattern of HTLV-III (AIDS-related) antigen recognition by sera from African children in Uganda (1972).
    Saxinger C; Levine PH; Dean A; Lange-Wantzin G; Gallo R
    Cancer Res; 1985 Sep; 45(9 Suppl):4624s-4626s. PubMed ID: 2990697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
    J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood.
    Barrett JE; Dawson G; Heller J; Bairstow C; Fico R; Webber JS; Gutierrez R; Decker RH
    Am J Clin Pathol; 1986 Aug; 86(2):180-5. PubMed ID: 3017089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III.
    Ward JW; Grindon AJ; Feorino PM; Schable C; Parvin M; Allen JR
    JAMA; 1986 Jul; 256(3):357-61. PubMed ID: 3014173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term serological follow-up of blood donors with an HTLV-indeterminate western blot: antibody profile of seroconverters and individuals with false reactions.
    Martins ML; Santos AC; Namen-Lopes MS; Barbosa-Stancioli EF; Utsch DG; Carneiro-Proietti AB
    J Med Virol; 2010 Oct; 82(10):1746-53. PubMed ID: 20827773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of antibodies against LAV/HTLV III: comparative evaluation of four different commercial test kits.
    Abb J
    AIDS Res; 1986; 2(2):93-7. PubMed ID: 3013224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HTLV-III antibodies after immune globulin.
    Piszkiewicz D
    JAMA; 1987 Jan; 257(3):316. PubMed ID: 3467073
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of three commercial screening tests for AIDS virus antibodies.
    Carlson JR; Hinrichs SH; Yee J; Gardner MB; Pedersen NC
    Am J Clin Pathol; 1986 Sep; 86(3):357-9. PubMed ID: 3019124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified Western blot assay for confirmation and differentiation of human T cell lymphotropic virus types I and II.
    Lipka JJ; Santiago P; Chan L; Reyes GR; Samuel KP; Blattner WA; Shaw GM; Hanson CV; Sninsky JJ; Foung SK
    J Infect Dis; 1991 Aug; 164(2):400-3. PubMed ID: 1856487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of HTLV-I ELISA-positive leukemia/lymphoma patients by western blotting gave mostly negative or indeterminate reaction.
    Srivastava BI; Gonzales C; Loftus R; Fitzpatrick JE; Saxinger CW
    AIDS Res Hum Retroviruses; 1990 May; 6(5):617-27. PubMed ID: 2113820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential neutralizing capacity to different human immunodeficiency virus (HIV) isolates by a rabbit antiserum against LAV: sensitive assays with HTLV-I-positive MT-4 cells.
    Yoshiyama H; Nakashima H; Kobayashi S; Yamamoto N
    AIDS Res Hum Retroviruses; 1988 Apr; 4(2):91-8. PubMed ID: 3284555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus.
    Lipka K; Tebbe B; Finckh U; Rolfs A
    Clin Exp Dermatol; 1996 Jan; 21(1):38-42. PubMed ID: 8689767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Liaison XL automated immunoassay platform for blood-borne infection screening on hepatitis B, hepatitis C, HIV 1/2, HTLV 1/2 and Treponema pallidum serological markers.
    Malm K; Kragsbjerg E; Andersson S
    Transfus Med; 2015 Apr; 25(2):101-5. PubMed ID: 25779614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of human immunodeficiency virus (LAV/HTLV-III)-reactive antibodies in African sera from southeastern Tanzania.
    Schüpbach J; Tanner M
    Acta Trop; 1986 Sep; 43(3):195-206. PubMed ID: 2877546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.